Javascript must be enabled to continue!
Modulation by a Sulfonylurea of Insulin-dependent Glycogenesis, but Not of Insulin Binding, in Cultured Rat Hepatocytes: Evidence for a Postreceptor Mechanism of Action
View through CrossRef
To detect potential direct effects of the sulfonylurea glyburide on hepatic carbohydrate metabolism, we tested whether the drug was capable of modulating insulin binding and glycogenesis in primary cultured hepatocytes. After 24-h culture under serum- and hormone-free conditions, cells were incubated with or without 10−8 M insulin and/or glyburide (0.1–5.0 μg/ ml) for another 24 h. Then, specific 125I-insulin binding and basal and insulin-stimulated glycogen synthesis were determined. Acute addition of glyburide to previously untreated cells did not modulate any of these parameters. Incubation for 24 h with 2 μg/ml of glyburide did not affect the DNA and protein content of the dishes. Cellular glycogen content and basal glycogenesis also remained unchanged by glyburide in hepatocytes incubated in the absence of insulin, but glycogen content was increased and basal glycogen synthesis decreased in insulin-pretreated cells. In contrast, glyburide increased insulin-stimulated glycogenesis in a dose-dependent fashion in both insulin-pretreated and control cells by enhancing responsiveness, but not sensitivity, toward insulin. Pretreating hepatocytes with 10−8 M insulin caused a 40% reduction in specific insulin binding. Glyburide did not modulate insulin binding or degradation in control cells nor was insulin-induced regulation of insulin receptors affected. These results demonstrate a direct dose-dependent effect of a sulfonylurea on an insulin action toward hepatic carbohydrate metabolism, and suggest that this effect is mediated by a postreceptor mechanism.
American Diabetes Association
Title: Modulation by a Sulfonylurea of Insulin-dependent Glycogenesis, but Not of Insulin Binding, in Cultured Rat Hepatocytes: Evidence for a Postreceptor Mechanism of Action
Description:
To detect potential direct effects of the sulfonylurea glyburide on hepatic carbohydrate metabolism, we tested whether the drug was capable of modulating insulin binding and glycogenesis in primary cultured hepatocytes.
After 24-h culture under serum- and hormone-free conditions, cells were incubated with or without 10−8 M insulin and/or glyburide (0.
1–5.
0 μg/ ml) for another 24 h.
Then, specific 125I-insulin binding and basal and insulin-stimulated glycogen synthesis were determined.
Acute addition of glyburide to previously untreated cells did not modulate any of these parameters.
Incubation for 24 h with 2 μg/ml of glyburide did not affect the DNA and protein content of the dishes.
Cellular glycogen content and basal glycogenesis also remained unchanged by glyburide in hepatocytes incubated in the absence of insulin, but glycogen content was increased and basal glycogen synthesis decreased in insulin-pretreated cells.
In contrast, glyburide increased insulin-stimulated glycogenesis in a dose-dependent fashion in both insulin-pretreated and control cells by enhancing responsiveness, but not sensitivity, toward insulin.
Pretreating hepatocytes with 10−8 M insulin caused a 40% reduction in specific insulin binding.
Glyburide did not modulate insulin binding or degradation in control cells nor was insulin-induced regulation of insulin receptors affected.
These results demonstrate a direct dose-dependent effect of a sulfonylurea on an insulin action toward hepatic carbohydrate metabolism, and suggest that this effect is mediated by a postreceptor mechanism.
Related Results
Potentiation of Insulin Action by a Sulfonylurea in Primary Cultures of Hepatocytes from Normal and Diabetic Rats
Potentiation of Insulin Action by a Sulfonylurea in Primary Cultures of Hepatocytes from Normal and Diabetic Rats
Although sulfonylureas have been used extensively in the treatment of non-insulin-dependent (type II) diabetes, controversy exists as to whether these agents act primarily by incre...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
1.Effect of chronic haloperidol treatment on D‐2 receptors labelled by (3H)‐spiperone in homogenates of rat corpus striatum. A. L. Gundlach, D. J. de Vries and P. M. Beart2.The eff...
Production of Hepatocytes Derived from Chicken Embryos Across Three Developmental Stages
Production of Hepatocytes Derived from Chicken Embryos Across Three Developmental Stages
Abstract
Background:
Chicken hepatocytes provide a valuable resource for conducting cell-based assays and gaining insights into...
Runahead threads
Runahead threads
Los temas de investigación sobre multithreading han ganado mucho interés en la arquitectura de computadores con la aparición de procesadores multihilo y multinucleo. Los procesador...
(Invited) A Protein-Based Artificial Receptor for Insulin Sensing
(Invited) A Protein-Based Artificial Receptor for Insulin Sensing
Insulin is one of the most important hormones that controls the glucose level in blood. Therefore, the investigation of insulin is very important for the diabetic research. There h...
Combined Insulin-Sulfonylurea Therapy in Treatment of NIDDM
Combined Insulin-Sulfonylurea Therapy in Treatment of NIDDM
For the past few years, interest has focused on the combination of insulin and sulfonylurea in the search for effective treatments for non-insulin-dependent diabetes mellitus (NIDD...
COMPARISON THE EFFECTIVENESS OF SITAGLIPTIN VERSUS SULFONYLUREA FOR MANAGEMENT OF PATIENTS WITH TYPE II DIABETES MELLITUS
COMPARISON THE EFFECTIVENESS OF SITAGLIPTIN VERSUS SULFONYLUREA FOR MANAGEMENT OF PATIENTS WITH TYPE II DIABETES MELLITUS
Background: Type 2 diabetes mellitus (T2DM) is characterized by prolonged hyperinsulinemia, insulin resistance, and progressive hyperglycemia. Current guidelines for treating patie...
Expression and characterization of rat kallikrein-binding protein in Escherichia coli
Expression and characterization of rat kallikrein-binding protein in Escherichia coli
Rat kallikrein-binding protein is a novel serine-proteinase inhibitor that forms a covalent complex with tissue kallikrein. We have purified rat kallikrein-binding protein and clon...

